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Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are
often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomy-
cin. Daptomycin is a ﬁrst-in-class cyclic lipopeptide that has proven efﬁcacy for the treatment of Gram-positive
infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the
clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal
infection models and has been used for the treatment of enterococcal infections in humans. In recent years,
large-scale susceptibility studies have shown that daptomycin is active against .98% of enterococci tested,
irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reﬂects the fact
that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides.
While there are limited data available from randomized controlled trials, extensive clinical experience with dap-
tomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone
and joint infections and urinary tract infections) has been reported. This growing body of evidence provides
useful insights regarding the efﬁcacy of daptomycin against enterococci in clinical settings.
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Introduction
Enterococci, particularly Enterococcus faecalis and Enterococcus
faecium, are among the leading pathogens isolated from
nosocomial infections.
1,2 Despite the availability of a number
of antimicrobial agents to treat enterococcal infections,
a substantial proportion of patients do not achieve adequate
outcomes,
1,3–5 due in part to an increase in the proportion
of enterococcal strains that are resistant to one or more of
these agents.
6–10 Additional therapeutic options are, therefore,
required for effective management of such patients.
Daptomycin is a cyclic lipopeptide that has rapid bactericidal
activity against a broad spectrum of Gram-positive bacteria.
11,12It
is indicated for the treatment of complicated skin and soft tissue
infections (cSSTIs) caused by susceptible Gram-positive bacteria,
right-sided infective endocarditis (RIE) due to Staphylococcus
aureus,a n dS. aureus bacteraemia (SAB) when associated with RIE
or cSSTI.
12 In clinical practice, daptomycin is commonly used to
treat enterococcal infections (often in patients with multiple
co-morbidities), occasionally at doses higher than 6 mg/kg, the
approved dosage to treat SAB.
12
There is a growing body of in vitro and clinical evidence
suggesting that daptomycin has good activity against
enterococci. This article evaluates the evidence for the role of
daptomycin in this clinical setting.
In vitro activity of daptomycin against
enterococci
Several studies have compared the activityof daptomycin against
clinical isolates of enterococci with those of currently licensed
agents (Table 1).
8,9,13–18In a surveillance study of clinical isolates
recovered during 2002–08 in the USA, .99.9% of 4496 E. faecalis
and .99.5% of 2875 E. faecium isolates were susceptible to
daptomycin, with MIC90s of 1 and 4 mg/L, respectively.
18 These
results were conﬁrmed by European surveillance carried out
between2005and2007thatincluded3385strainsofenterococci,
which showed a daptomycin susceptibility rate of 100%, with the
MIC90s of daptomycin for E. faecalis and E. faecium being 1 and
2 mg/L, respectively.
15 In both studies, the MIC90 of daptomycin
was at or below the CLSI daptomycin susceptibility breakpoint
for enterococci of ≤4 mg/L, which also corresponds to the
epidemiological cut-off values for E. faecalis and E. faecium
established by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST).
19,20 Daptomycin demonstrated
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1126Table 1. Susceptibility of enterococci to antibiotic agents in multicentre, comparative studies worldwide
Daptomycin Linezolid Vancomycin
Quinupristin/
dalfopristin
Study
year Region Source of isolates Enterococcus species
No. of
isolates MIC90
%
susceptibility MIC90
%
susceptibility MIC90
%
susceptibility MIC90
%
susceptibility Reference
2006 USA bacteraemia,
wound or other
infections
enterococci 547 2 99.8 2 97.4 .16 71.7 .2 31.1 8
2004–05 Europe various infection
types
VSE 484 4 100 2 99.8 0.5 99.8 ND ND 9
VRE 195 4 100 2 100 ≥64 21.7 ND ND
2007 Europe various infection
types
VSE 542 4 100 2 95.4 0.5 100 ND ND 9
VRE 187 4 100 2 95.7 ≥64 21.4 ND ND
2005–07 Europe bloodstream, skin
or other
infections
VSE 15
E. faecium 853 2 100 2 99.8 1 100 .2 70.6
E. faecalis 2133 1 100 2 100 2 100 .2 0.9
VRE
E. faecium 267 2 100 2 99.3 .16 0 .2 78.3
E. faecalis 18 1 100 2 100 .16 0 .20
2002–05 USA/Canada various infection
types
VSE 3336 2 99.9 2 99.8 ND ND .2 11.2 14
VRE 1560 4 99.4 2 98.5 ND ND 2 86.9
2005–08 Europe bloodstream
infections
vancomycin-resistant
E. faecium
134 2 99.3 2 98.5 ND ND .2 73.1 16
2005–06 Canada various infection
types in ICU
patients
E. faecalis 91 1 100 2 92.3 2 97.8 ND ND 17
E. faecium 29 2 100 8 34.5 .64 72.4 ND ND
VRE 17 1 100 4 64.7 .64 0 ND ND
other enterococci 135 1 100 2 97.2 2 94.7 ND ND
2007–08 USA/Korea blood or skin
infections
E. faecalis (USA/Korea) 455 2 100 2 96.9 4 96.0 32 0.9 13
E. faecium (Korea) 184 4 100 2 95.7 .128 73.4 4 78.8
E. faecium (USA) 205 4 98.5 4 85.9 .128 20.0 2 71.7
ICU, intensive care unit; ND, not determined; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.
All MIC data were measured using broth microdilution.
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Cexcellent in vitro activity against enterococcal isolates recovered
from patients at high risk of developing infections due to
antibiotic-resistant bacteria, such as patients with cancer or in
intensive care units.
17,21 Studies have also shown that other
enterococcalspecies,includingEnterococcusdurans,Enterococcus
avium, Enterococcus casseliﬂavus, Enterococcus gallinarum and
Enterococcus rafﬁnosus, are susceptible to daptomycin.
22–24
Activity of daptomycin against enterococci growing as
bioﬁlms
Bioﬁlms are populations of bacterial cells attached irreversibly on
various human and artiﬁcial surfaces and encased in a hydrated
matrix mainly composed of exopolymeric substances and poly-
saccharides. According to the NIH in the USA, bioﬁlms account
for .80% of microbial infections in the body.
25 It has been
suggested that the ability of enterococci to form bioﬁlms may
be facilitated by the production of enterococcal surface
protein.
26–28 Enterococci develop persistent bioﬁlms on a wide
variety of medical devices that are commonly used in hospital-
ized patients, and this may partially explain why they are one
of the leading causes of nosocomial infections.
Bioﬁlms are difﬁcult to eradicate because they restrict the dif-
fusion and target accessibility of antimicrobial agents. Moreover,
bacterial cells in bioﬁlms (sessile bacteria) have slower growth
rates and can tolerate 10- to 1000-fold higher concentrations
of antibiotics than planktonic bacteria.
27 Therefore, the bioﬁlm
matrix is generally considered as a platform for the development
of drug-resistant bacteria. The persistence of bioﬁlms on medical
devices may contribute to prolonged infection, thereby increas-
ing the opportunity for patient-to-patient transmission.
The eradication of bioﬁlms requires an antibiotic that can
effectively penetrate the bioﬁlm matrix and is active against
slow-growing bacteria. Daptomycin is bactericidal against
stationary-phase bacteria and has good penetration into the
bioﬁlm matrix to effectively reduce bacterial growth.
29,30 In con-
trast, some reports have shown ineffective killing of E. faecalis
growing in bioﬁlms using vancomycin.
31,32 In an in vitro bioﬁlm
model (using silicone discs), daptomycin was signiﬁcantly
superior to quinupristin/dalfopristin and linezolid in reducing
the growth of vancomycin-resistant E. faecalis isolated from
patients with catheter-related bacteraemia (P,0.01; Table 2).
33
Activity of daptomycin against antibiotic-resistant
enterococci
The increasing prevalence of infections caused by vancomycin-
resistant enterococci (VRE) has been documented globally.
10,34
Enterococcal strains resistant to several non-glycopeptide anti-
biotic agents, including ampicillin, quinupristin/dalfopristin and/
or linezolid, have also been reported.
7–9
In a recent surveillance study performed across 50 medical
centres in the USA, 28% of enterococci isolates were resistant
to vancomycin.
8 Moreover, surveillance of enterococcal infec-
tions in the USA showed that between 2002 and 2008, only
20.2% of E. faecium isolates (n¼2875) were susceptible to van-
comycin.
18 In Europe, the VRE rate increased from 4.5% in 2006
to 10.2% in 2007, although the prevalence varied signiﬁcantly
from country to country. For example, in 2007 there were no
reports of VRE in either Switzerland or Spain, but the prevalence
of VRE was 25.8% and 23.8% in Ireland and Poland, respectively.
Among E. faecium strains, the vancomycin resistance rate in
Europe increased from 17.9% in 2005 to 26.3% in 2007.
15
Similar trends were seen in the European Antimicrobial Resist-
ance Surveillance System (EARSS).
10,35
Resistance to vancomycin is conferred by a number of van
genes, of which vanA and vanB are the most prevalent.
7,10 In
2007, 76% of VRE isolates in North America and 40% of isolates
in Europe exhibited the VanA phenotype.
7 Although the majority
of clinical enterococcal isolates are E. faecalis, E. faecium is
the more prevalent species among VRE.
7,28 The increase in the
incidence of VRE in the hospital setting is mainly due to the
emergence of vancomycin resistance among a subpopulation
of E. faecium known as clonal complex 17 (CC17).
7,28 Nearly
all E. faecium isolates belonging to CC17 are resistant to
ampicillin and partially resistant to quinolones. CC17 E.
faecium isolates also possess additional genetic determinants,
including putative virulence genes, such as those encoding
different cell wall-anchored surface proteins.
28 It appears that
a large number of genes acquired by CC17 E. faecium contribute
to its selective advantage; this, together with its inherent anti-
biotic resistance, facilitates the further dissemination of VRE in
the hospital environment.
28,36 Daptomycin has effective in
vitro activity against E. faecium isolates belonging to CC17 (P.
Ruiz-Garbajosa, T. M. Coque, F. Baquero and R. Canto ´n, unpub-
lished data).
As the mode of action of daptomycin is distinct from that of
glycopeptides, its activity against enterococci is unaffected by
the presence of the van genes. Studies have shown that most
enterococci are susceptible to daptomycin, irrespective of their
resistance towards vancomycin.
8,14–16,22,37 Among VRE, dapto-
mycin MICs ranged from 1 to 4 mg/L for isolates with the VanA
phenotype,
38 and daptomycin was also active against those
with VanB or VanC phenotypes.
22 In an analysis of the antimicro-
bial susceptibility of Gram-positive bacteria collected in European
and Israeli medical centres from 2005 to 2007, all 285 VRE
Table 2. Daptomycin demonstrated superior activity over comparator
antibiotics in reducing the growth of 22 vancomycin-resistant E. faecalis
isolates from catheter-related bacteraemia patients in bioﬁlms
(extracted from the study by Raad et al.
33)
Antibiotic or control MIC range (mg/L)
Bioﬁlm (mean cfu per
disc+SEM)
a
Daptomycin 2.0–8.0 1.3×10
2+2.7×10
1
Minocycline ≥0.06–8.0 5.6×10
2+1.2×10
2
Quinupristin/dalfopristin ≥0.06–2.0 3.0×10
3+1.8×10
2
Linezolid 0.5–2.0 4.3×10
3+1.4×10
2
Control (water) NA 5.0×10
3+0
NA, not applicable; SEM, standard error of the mean.
aColonization data are after 24 h of exposure to 2000 mg/L antibiotic.
All antibiotics signiﬁcantly reduced bioﬁlm colonization compared with
the control (P≤0.01). Daptomycin was more effective than minocycline
(P,0.001). Minocycline was signiﬁcantly more effective than quinupris-
tin/dalfopristin (P,0.01) and quinupristin/dalfopristin was signiﬁcantly
more effective than linezolid (P,0.01). A total of 660 discs were tested
using six discs per isolate plus a particular antibiotic or water.
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cin for vancomycin-non-susceptible E. faecalis and E. faecium
were 1 and 2 mg/L, respectively.
15 When tested against blood-
stream isolates, 99.3% of vancomycin-resistant E. faecium iso-
lates were susceptible to daptomycin, 98.5% to linezolid and
73.1% to quinupristin/dalfopristin.
16 Daptomycin showed
greater inhibitory activity against glycopeptide-
resistant enterococci (GRE) than linezolid (MIC90 1.5 mg/L
versus 4.0 mg/L),
37 and was also more active against VRE than
linezolid or quinupristin/dalfopristin in time–kill studies.
11
Furthermore,invitrotime–kill,agardiffusionandchequerboard
studies demonstrated synergistic effects of daptomycin with
rifampicin or ampicillin against VRE, including linezolid-resistant
strains. No antagonism of daptomycin with these agents was
seen.
39–41 Other in vitro data also showed that daptomycin has
non-antagonistic effects with gentamicin and b-lactams against
vancomycin-susceptible enterococci and VRE,
42 suggesting that
combination therapy may be beneﬁcial in certain clinical situ-
ations, such as in neutropenic patients.
43 Nevertheless, clinical
data for this beneﬁcial effect are still scarce.
Additional reports have documented that enterococci are fre-
quently also resistant to antibiotics other than vancomycin. In
the 2005 SENTRY antimicrobial surveillance programme, which
evaluated 953 enterococci isolates from medical centres in 10
European countries, Turkey and Israel, 49.5% and 29.2% of
the isolates were resistant to ciproﬂoxacin and ampicillin,
respectively.
44 This could possibly be a consequence of CC17
E. faecium expansion.
28 The programme also found quinupristin/
dalfopristin to be inactive against 10% of E. faecium isolates.
7
As expected, daptomycin activity against enterococci was not
inﬂuenced by their susceptibility to ampicillin or quinupristin/dal-
fopristin.
22,45 Furthermore, of 1000 E. faecium clinical isolates
tested in Greece, 2.5% were resistant to linezolid and 15% were
resistant to quinupristin/dalfopristin, but none was resistant to
daptomycin. As in previous studies, there were no differences
in daptomycin MICs for isolates that were resistant or
susceptible to other antibiotics. In particular, the activity of
daptomycin was not reduced against enterococci resistant to
vancomycin or linezolid.
45 Daptomycin also demonstrated rapid
bactericidal activity against ampicillin-resistant enterococci,
and its activity was not compromised when tested simul-
taneously with aminoglycosides.
46 Other in vitro studies also
showed daptomycin to be bactericidal against aminoglycoside-
resistant or penicillinase-producing enterococci.
47
Linezolid-resistant enterococci have been isolated from clini-
cal specimens.
8,9,48 Surveillance in the USA during 2006
showed that nearly 2% of enterococci tested were resistant to
linezolid,
8 while in Europe the frequency of enterococci non-
susceptible to linezolid increased from 0.1% in 2004/2005 to
4.7% in 2007.
9 A German study of 60 clinical isolates reported
that a high proportion of glycopeptide-resistant E. faecium
(82%) exhibited intermediate susceptibility to linezolid,
37 which
could be due to over-representation of speciﬁc GRE strains due
to clonal spread.
49,50 In all these studies, daptomycin remained
active against enterococci regardless of the susceptibility to line-
zolid, with MICs ranging from 0.06 to 4 mg/L.
9 In a separate
in vitro study of linezolid-resistant clinical isolates, daptomycin
inhibited all enterococcal isolates (n¼68) at ≤4 mg/L, and the
majority of E. faecalis (93.3%) and E. faecium (94.3%) strains
had daptomycin MICs of ≤1 and ≤2 mg/L, respectively.
51
Evidence from animal models
In vivo evidence further suggests the efﬁcacy of daptomycin in
enterococcal infections, including those involving GRE. In a rat
model of endocarditis, daptomycin at standard recommended
human doses (6 mg/kg every 24 h) showed similar efﬁcacy to
amoxicillin and vancomycin, and was signiﬁcantly (P,0.05)
more effective than teicoplanin against glycopeptide-susceptible
E. faecalis isolates. Moreover, daptomycin was also superior to
teicoplanin in the treatment of endocarditis due to VanB
vancomycin-resistant E. faecium.
52 These results are consistent
with the ﬁndings of an in vitro model of simulated endocardial
vegetations. In this model, a simulated regimen of daptomycin
at 6 mg/kg every 24 h demonstrated signiﬁcant bactericidal
activity against a strain of vancomycin-resistant E. faecium.
53
Another study showed that high-dose daptomycin (12 mg/kg),
alone or in combination with gentamicin, was effective in a
rabbit model of endocarditis caused by E. faecium.
54 Daptomycin
also showed rapid bactericidal activity against vancomycin-
resistant E. faecium in a pharmacodynamic model, with no
development of resistance despite subinhibitory antimicrobial
activity.
55 In addition, studies with murine renal and thigh infec-
tion models showed that clinically relevant exposure to dapto-
mycin was effective against enterococci.
56,57
Complementing data from in vitro time–kill studies, daptomy-
cin demonstrated excellent bactericidal activity and dose-
dependent reductions in bacterial counts in these animal
models, supporting the potential beneﬁts for the treatment of
enterococcal infections in humans.
Clinical experience with daptomycin in
enterococcal infections
Considerable clinical experience with daptomycin in enterococcal
infections is available in the form of published case reports,
case series and the Cubicin Outcomes Registry and Experience
(CORE
w) database. CORE is a retrospective, post-marketing data-
base that includes information on prescribing patterns and out-
comes with daptomycin therapy in the USA.
58
Bacteraemia
Using the CORE database, Mohr et al.
59 analysed clinical out-
comes of patients with enterococcal bacteraemia who were
treated with daptomycin. A total of 159 patients with entero-
coccal bacteraemia, comprising 120 patients with E. faecium
(91% vancomycin resistant) and 39 with E. faecalis (23%
vancomycin resistant), were treated with daptomycin either as
ﬁrst-line therapy (17%) or after prior treatment with other anti-
biotic agents.
59 The overall clinical success rate was 87%, with
similar rates between patients infected with E. faecium (87%)
and those infected with E. faecalis (90%). Clinical outcomes
were not inﬂuenced by the use of concomitant antibiotic
therapy, and clinical success was reported in 87% of those
patients who received prior vancomycin and 88% of patients
who did not. The clinical outcome in relation to dosage schedule
for daptomycin was not reported.
59
Vancomycin resistance is independently associated with
increased mortality among patients with bacteraemia due to
Review
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60,61 The fact that patients with bacteraemia due to
VRE are also less likely to receive appropriate therapy than those
with vancomycin-susceptible enterococcal bloodstream infec-
tions
62,63 highlights a lack of appropriate therapeutic options
for these patients. The Infectious Diseases Society of America
2009 guidelines recommend the use of daptomycin for the treat-
ment of catheter-related bacteraemia due to VRE or ampicillin-
resistant enterococci in patients with or without dialysis.
64
A recent retrospective chart review included the medical
records of 30 patients with bacteraemia due to VRE who received
a median daptomycin dose of 6 mg/kg (range, 3.7–8 mg/kg). All
isolates were susceptible to daptomycin, with MICs ranging from
,1 to 4 mg/L, and this is reﬂected in the microbiological
cure rate of 80%, while clinical success was observed in
17 patients (59%). The authors suggested that the efﬁcacy rate
of daptomycin would have been higher if all patients received a
6m g / k g / d o s e .
65 Segreti et al.
66 also reported a retrospective
series of patients with bacteraemia due to Gram-positive bacteria
who were treated with daptomycin. Among nine patients with
bacteraemia without endocarditis due to VRE (most of whom
had received previous therapy with vancomycin or linezolid), ﬁve
achieved successful resolution of infection after treatment with
daptomycin at 4–6 mg/kg (four received monotherapy and one
received daptomycin in combination with tobramycin). Treatment
was not successful in the remaining four patients who received
6 mg/kg daptomycin (three received concomitant aminoglyco-
sides). All four of these patients died, but they all had other
serious co-morbidities.
66 Two cases of bacteraemia due to VRE
successfully treated with daptomycin at a dosage of 4 mg/kg
were reported by Kvirikadze et al.;
67 a further case reported a
patient with bacteraemia caused by a vancomycin-susceptible
strain of E. faecalis unresponsive to vancomycin therapy who
was also treated successfully with 12 mg/kg daptomycin.
68
Although daptomycin is not approved for the treatment of
enterococcal bacteraemia, there is growing evidence from clinical
practice that doses higher than the currently approved dose
(e.g. 8–12 mg/kg once a day) may be required for optimal treat-
ment of complicated enterococcal infections.
69–71
Several reports have focused on the use of daptomycin for the
treatment of enterococcal bacteraemia in neutropenic patients.
In a study of 92 allogeneic haematopoietic stem cell recipients,
34 patients developed bloodstream infections, of which
14 (41%) were due to VRE (13 E. faecium and 1 E. avium). Ten
of these patients received daptomycin, three of whom were
reported as microbiological failures; however, the infecting
strains remained susceptible to daptomycin in vitro in all three
cases. This observation, coupled with the fact that all 10 patients
treated with daptomycin had also received linezolid or other
antibiotics, highlights the inherent difﬁculty in interpreting
microbiological outcomes. In addition, the clinical picture was
complicated by the presence of underlying conditions in these
patients and the absence of a comparator group.
72 Nine febrile
neutropenic patients with bacteraemia due to VRE (eight
E. faecium and one E. faecalis) were treated with daptomycin
in an open-label emergency-use trial. Four patients (44%)
achieved clinical and/or microbiological cure; two patients died
within 3 days of commencement of treatment, indicating the
severity of their illnesses. No correlation between clinical or
microbiological outcome and daptomycin dose (4 or 6 mg/kg)
was apparent; in fact, the small number of patients makes it
difﬁcult to draw meaningful conclusions from this study.
69
More recently, treatment failure was observed in 13 of 31 bacter-
aemic patients treated with daptomycin, 6 of which were due to
relapses within 1 month of initiation of initial infection.
73
Successful treatment with daptomycin combination therapy
in patients with bacteraemia has also been reported.
43,74 In
one case, a 21-day-old full-term infant developed bacteraemia
due to vancomycin-resistant E. faecium 10 days after heart
surgery (endocarditis was suspected but not conﬁrmed). Bacter-
aemia persisted despite the removal of vascular catheters and
treatment with antibiotics (including linezolid, quinupristin/dalfo-
pristin, ampicillin/sulbactam and rifampicin). Microbiological cure
was achieved with a combination regimen that initially included
daptomycin (4 mg/kg every 48 h) in combination with gentami-
cin, but with the dose of daptomycin subsequently increased
to 6 mg/kg every 24 h in combination with gentamicin and
doxycycline.
74
Two retrospective studies have attempted to compare dapto-
mycin with linezolid for the treatment of bacteraemia due to
VRE. In a study by Mave et al.
75 in 98 adult patients, 68 of
whom received linezolid and 30 of whom received daptomycin,
the microbiological cure rates were 88.2% and 90%, respectively.
No statistically signiﬁcant differences in clinical outcomes were
observed. Differences in the baseline characteristics of the treat-
ment groups (signiﬁcantly higher proportions of patients in inten-
sive care units and patients with concomitant SAB in the
daptomycin group) precluded any conclusive statements about
the comparative performance of the two compounds. Similar
results were described for daptomycin and linezolid in a study
of neutropenic cancer patients by Marion et al.
76 Clearance of
blood cultures was seen in 17 (81%) of 21 patients who received
daptomycin, and 8 (80%) of 10 patients who were treated with
linezolid. Relapse of infection was seen in 19.1% and 20% of
the patient treatment groups, respectively. Overall mortality in
the two patient cohorts was 52.3% and 60%, respectively.
76
Infective endocarditis (IE)
In an analysis of the CORE database, Enterococcus was identiﬁed
as the primary pathogen in 14 of 49 patients with IE. Clinical
success was reported in 10 of 14 patients [9 with left-sided IE
(LIE) and 1 with RIE], and 2 patients failed daptomycin therapy
(1 with LIE and 1 with RIE). Outcomes were not evaluable for
the remaining two patients.
77 Case reports of daptomycin for
IE caused by Enterococcus spp. have yielded various outcomes,
including death in some cases (Table 3). It should be noted,
however, that all patients in these cases had signiﬁcant under-
lying co-morbidities, with the majority failing prior antibiotic
treatment. Daptomycin was usually given in combination with
other antibiotics with no standardization as to concomitant
treatment, and it was unclear whether cases of mortality were
attributable to endocarditis or the underlying co-morbidity.
One recent case report detailed successful combination treat-
ment with high-dose daptomycin (8 mg/kg every 24 h), gentami-
cin (1 mg/kg every 12 h) and ampicillin (16 g every 24 h) in a
patient with LIE caused by a strain of E. faecium ‘heteroresistant’
to vancomycin, but susceptible to daptomycin (MIC,4 mg/L).
Previous treatment with daptomycin (6 mg/kg) monotherapy
cleared blood cultures, but persistent vegetation was detected
5 weeks after the start of treatment and the patient refused
Review
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substituted by vancomycin plus gentamicin. These therapies
were subsequently stopped after detection of VRE in blood
cultures. Finally, the combination of high-dose daptomycin
(8 mg/kg every 24 h), gentamicin and high-dose ampicillin
(16 g every 24 h), given over 6 weeks, cured the infection.
78
In a separate case of endocarditis due to a strain of
linezolid-resistant VRE (MICs: linezolid, 12 mg/L; and daptomycin,
3 mg/L), and the patient was successfully treated with high-dose
daptomycin (started at 6 mg/kg every 24 h and subsequently
increased to 8 mg/kg every 24 h) in combination with rifampicin,
gentamicin and tigecycline.
79 Despite this evidence, more clinical
data are needed to deﬁne the role of daptomycin (alone or in
combination) therapy in enterococcal endocarditis.
Skin and soft tissue infections (including surgical site
infections)
In the pivotal studies, E. faecalis was the third most frequently
treated pathogen (11.8%), and the clinical success rate among
patients with cSSTI due to E. faecalis was 73.0% for daptomycin
and 75.5% for the comparators (cloxacillin, ﬂucloxacillin, nafcil-
lin, oxacillin or vancomycin).
80 A report from the CORE database
analysing patients with surgical site infections found that
Enterococcus spp. were the second most common pathogen,
being isolated from 23 (22%) of 104 evaluable patients. Eight
of these 23 patients had VRE (7 E. faecium), of which 5 had
organ/space infection. Enterococcus was considered to be the
primary pathogen in 16 of these 23 patients, with clinical
success reported for 14 (88%) patients. The success rate for
patients with any VRE was 63% (ﬁve of eight patients). VRE
was found to be an independent risk factor for treatment
failure (odds ratio 14.2; 95% conﬁdence interval 1.3–154).
81
In an analysis of 522 evaluable patients with skin and soft
tissue infections registered in the CORE database in 2004,
337 patients (65%) yielded Gram-positive pathogens on
culture, 63 (19%) of which were Enterococcus spp. that included
28 VRE cases. In 48 patients where an Enterococcus sp. was con-
sidered to be the primary pathogen, clinical success was noted in
44 patients (92%).
82
Bone and joint infections
The CORE database also collects data for patients receiving dap-
tomycin for the treatment of osteomyelitis.
83 Clinical outcomes
were evaluated at the end of therapy (EOT group) and for
patients who had one or more follow-up post-treatment assess-
ments 3–13 months after the end of therapy (PT group). Of
148 patients with osteomyelitis registered during 2004, 12 and
8 patients in the EOT and PT groups, respectively, had infections
due to enterococci. Outcomes for patients in the EOT group with
enterococcal infections were not reported, but six of the eight
patients in the PT group where enterococci were considered to
be the primary pathogen were reported as having successful
clinical outcomes, while two patients failed therapy. This was
similar to the overall clinical success rate of 82% (55 of
67 patients) in the PT group.
Other infections
A small number of publications documenting the use of dapto-
mycin for the treatment of other enterococcal infections have
appeared recently in the literature. Two reports concerned
lower urinary tract infections (UTIs), which is a potential area
of interest because  50% of the daptomycin dose is excreted
as unchanged drug in urine over 24 h following intravenous
administration.
84 One open-label, single-blinded study compared
daptomycin and ciproﬂoxacin for the treatment of adults with
complicated UTIs caused by Gram-positive pathogens.
85 A
total of 68 patients were randomized to receive daptomycin
(4 mg/kg every 24 h) or ciproﬂoxacin (400 mg every 12 h) for
5–14 days. Of 45 patients treated for enterococcal UTI,
Table 3. Case reports of endocarditis due to vancomycin-resistant enterococci treated with daptomycin
Patient
Underlying conditions
Dose
(mg/kg)
Pathogen
(all VAN-resistant)
Concomitant
antibiotics Prior antibiotics Outcome Reference age sex
64 F haemodialysis, prosthetic valve 6 Enterococcus spp.
a TOB none died 66
b
51 M not reported 6 Enterococcus spp.
a AMK VAN died 66
b
25 F SLE, ESRD 8 E. faecium GEN, RIF LZD died 103
62 M diabetes, coronary and peripheral
arterial disease, ESRD
6 E. faecium TGC VAN, LZD, MEM, FLC recovered 104
60 M diabetes 6/8
c E. faecium AMP, GEN FEP, VAN recovered 78
13 M GVHD, pancreatitis 6/8
c E. faecium NR VAN, MEM, GEN died 105
70 M renal failure (receiving haemodialysis) 6/8
c E. faecium GEN, DOX LZD failure 106
AMK, amikacin; AMP, ampicillin; DOX, doxycycline; ESRD, end-stage renal disease; F, female; FEP, cefepime; FLC, ﬂuconazole; GEN, gentamicin; GVHD,
graft-versus-host disease; LZD, linezolid; M, male; MEM, meropenem; NR, not reported; RIF, rifampicin; SLE, systemic lupus erythematosus; TGC,
tigecycline; TOB, tobramycin; VAN, vancomycin.
aSpecies not stated.
bPatients who were included in a CORE analysis.
cInitial dose of 6 mg/kg increased to 8 mg/kg.
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JACTable 4. Case reports of infections with daptomycin-non-susceptible enterococci isolates
Patient
Underlying
conditions
Indication for DAP use
DAP treatment DAP MIC, mg/L
Other antibiotic
used/surgery Final outcome Reference age sex pathogen type of infection
53 M NR VAN-resistant E. faecalis endocarditis
(mitral valve)
6 mg/kg every 24 h
for 8 weeks
(followed by
mitral valve
replacement)
.8 (Etest) prior: NAF, VAN bacteraemia
10 days after
discharge and
died soon
afterwards
96
follow-on: LZD
55 F diabetes mellitus,
haemodialysis,
AICD
E. faecalis endocarditis
(aortic valve)
6 mg/kg every 48 h 32 (microdilution) follow-on: AMP,
GEN, aortic valve
replacement,
tricuspid
valvuloplasty,
removal of AICD
cured 97
22 M Hodgkin’s
lymphoma, AML,
testicular
carcinoma
VAN-resistant
E. faecium, E. coli
bacteraemia 6 mg/kg every 24 h
for 17 days
.32 (microdilution) prior: DOX, FEP, VAN,
metronidazole
cured 98
concomitant: MEM
follow-on: LZD,
DOX, catheter
removal
37 F AML VAN-resistant E. faecium bacteraemia 6 mg/kg for 17 days .32 (microdilution) prior: TZP, GEN, VAN,
AMB, VRC
recurrence of VRE
bacteraemia
99
follow-on: LZD,
catheter removal
62 F myeloﬁbrosis, GVHD VAN-resistant E. durans bacteraemia 6 mg/kg every 48 h
for 20 days
32 (Etest) prior: FEP, LVX cured 95
follow-on: LZD,
catheter removal
NR M Crohn’s disease VAN-resistant E. faecium bacteraemia NR 16 (Etest) prior: Q/D NR 94
64 F cryptogenic
cirrhosis,
haemodialysis
VAN-resistant E. faecalis bacteraemia 400 mg every 48 h
for  14 days
16 (microdilution) prior: LZD died 100
concomitant: AMK
follow-on: LZD, AMP
AICD, automated implantable cardioverter-deﬁbrillator; AMB, amphotericin B; AMK, amikacin; AML, acute myeloid leukaemia; AMP, ampicillin; DAP, daptomycin; DOX, doxycycline;
F, female; FEP, cefepime; GEN, gentamicin; GVHD, graft-versus-host disease; LVX, levoﬂoxacin; LZD, linezolid; M, male; MEM, meropenem; NAF, nafcillin; NR, not reported;
Q/D, quinupristin/dalfopristin; TZP, piperacillin/tazobactam; VAN, vancomycin; VRC, voriconazole; VRE, vancomycin-resistant enterococci.
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222 patients with E. faecalis infections received daptomycin and
23 (21 with E. faecalis and 2 with E. faecium infections) received
ciproﬂoxacin. The microbiological eradication rate was 81.8%
(18 of 22 patients) for daptomycin and 78.3% (18 of 23 patients)
for ciproﬂoxacin.
85 In a separate report, ﬁve hospitalized patients
with UTIs due to multidrug-resistant VRE (species not indicated)
were treated with 250 mg/day of daptomycin (equivalent to
1.4–3.7 mg/kg) for 5 days, because the authors speculated
that urinary accumulation of daptomycin should allow for
lower dosing. In all ﬁve patients, urine cultures 2 days after com-
pletion of therapy were negative, and follow-up 10–14 days
after therapy revealed no recurrence of bacteriuria.
86 It should
be noted that patients with enterococcal UTIs may be at risk
of complications such as bacteraemia, and no strong rationale
exists for the use of daptomycin doses lower than those doses
shown to be safe in clinical studies,
80,87 and subsequently
approved for cSSTI (4 mg/kg) and SAB with or without IE
(6 mg/kg).
12
Daptomycin has also been used successfully in two patients
receiving peritoneal dialysis for end-stage renal disease who
developed peritonitis due to VRE.
88 Each patient was treated
for 10 or 14 days with intraperitoneal daptomycin (20 mg/L),
given every 4 h through peritoneal dialysate exchanges. The
treatment was successful despite the known degradation
of daptomycin in dextrose solution. A separate case report
also showed that intraperitoneal daptomycin (15 mg/kg once
weekly) was successful in the treatment of continuous ambulatory
peritoneal dialysis-related peritonitis due to vancomycin-resistant
E. faecium.
89
Successful treatment of external ventricular drain-associated
ventriculitis caused by E. faecalis with intraventricular daptomy-
cin has also been reported.
90
Resistance of enterococci to daptomycin
Neither the CLSI nor the EUCASTcommittees have deﬁned resist-
ance breakpoints for enterococci to daptomycin. According to the
CLSI,enterococciisolateswithdaptomycinMICs≤4 mg/Larecon-
sidered susceptible to the drug. Only rare occurrences of isolates
displaying MIC values higher than the susceptible breakpoint
have been described.
20,91Moreover, enterococci with daptomycin
MICs .4 mg/L (CLSI susceptible breakpoint of ≤4 mg/L) are often
designated as resistant or as non-susceptible.
Few in vitro resistance studies have been performed with dap-
tomycin and enterococci, and the mechanism underpinning this
resistance remains to be elucidated. Spontaneous resistance to
daptomycin in enterococci occurs rarely in vitro, with frequencies
,10
29.
92 In one study, enterococci and staphylococci obtained
from agar plates that contained daptomycin (at concentrations
above the MIC) failed to grow when subcultured on daptomycin-
containing agar plates. After puriﬁcation on agar plates without
daptomycin, these bacteria exhibited MICs identical to those for
the parent strains. This suggested that susceptibility to daptomy-
cin is heterogeneous.
92
Daptomycin-non-susceptible E. faecium (with an MIC of
6 mg/L) was recovered from a patient with bacteraemia who
had no previous exposure to daptomycin.
93 However, the
study did not investigate the potential mechanisms underlying
the reduced susceptibility of daptomycin. Treatment failures of
enterococcal infections associated with reduced daptomycin
susceptibility have been reported (Table 4),
94–100 including
ﬁve cases of bacteraemia
94,95,98–100 and two cases of endo-
carditis.
96,97 The majority of these infections were due to
VRE.
94–96,98–100 In six out of these seven treatment failure
cases, patients had received daptomycin treatment prior to the
detection of a resistant strain, suggesting that the resistance
developed during treatment;
95–100 however, it is difﬁcult to
draw ﬁrm conclusions regarding this because baseline MICs
for daptomycin were not available in most cases.
94–97,99,100
The daptomycin MICs for these E. faecium and E. faecalis
isolates ranged from .8t o.32 mg/L
94,98,99 and from .8t o
32 mg/L,
96,97,100 respectively. The conditions of these patients
were complicated by other underlying diseases. Five of these
cases involved foreign bodies,
95–98,100 and the removal of pros-
thetic devices was delayed in four cases.
95–98 Furthermore, the
daptomycin doses used in three of six cases with a known
dosing regimen were ,6 mg/kg every 24 h, which may be
suboptimal for the treatment of enterococcal endocarditis or
bacteraemia (the CLSI susceptibility breakpoint and the EUCAST
epidemiology cut-off value for enterococci are greater than
that for S. aureus).
12,19,20,87,101,102
Conclusions
Treatment for enterococcal infections is becoming increasingly
challenging, because enterococci may develop resistance to
existing therapies and there is a paucity of therapeutic
options against multidrug-resistant enterococci. Using the
CLSI breakpoint of ≤4 mg/L and the EUCAST epidemiological
cut-off value of 4 mg/L, microbiological data show that the
large majority of clinical enterococcal isolates are susceptible
to daptomycin. Furthermore, daptomycin is not associated
with cross-resistance to other antimicrobials and is active
against most isolates of antibiotic-resistant enterococci,
including VRE. Current clinical practice suggests that daptomy-
cin alone or combined with other agents can achieve favour-
able outcomes in patients with enterococcal infections,
including those with multiple co-morbidities. Further clinical
experience, including additional safety and efﬁcacy studies
with higher doses of daptomycin (8–12 mg/kg), will be useful
in better characterizing the role of daptomycin in enterococcal
infections.
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